Terminated PHASE1 INTERVENTIONAL 3-arm NCT06162299

A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002

A Phase I, Double-blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 in the Treatment of Chronic Hepatitis B (CHB) Infection in Adults ≥ 18 Years Old

Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.

Conditions Chronic Hepatitis B

Interventions YS-HBV-002

Updated 6 times since 2024 Last updated: Feb 20, 2025 Started: Jul 1, 2024 Primary completion: Sep 30, 2024 Completion: Oct 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business strategy

Other Chronic Hepatitis B trials with similar outcome

Browse all Chronic Hepatitis B trials

Listed as NCT06162299, this PHASE1 trial focuses on Chronic Hepatitis B and remains terminated or withdrawn. Sponsored by Yisheng Biopharma (Singapore) Pte. Ltd., it has been updated 6 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Mar 2025 — Sep 2025 [monthly]

Terminated PHASE1

Status: Not Yet Recruiting → Terminated
Sep 2024 — Mar 2025 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

▶ Show 1 earlier version

Jan 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yisheng Biopharma (Singapore) Pte. Ltd.

Data source: Yisheng Biopharma (Singapore) Pte. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Iloilo City, Philippines